Insulin-like growth factor-I stimulates acromegaly-like specific mandibular enlargement in rats
Insulin-like growth factor-I stimulates acromegaly-like specific mandibular enlargement in rats
复制标题
DOI：
10.1055/s-2004-826019
复制
发表时间：
2004-10-01
影响因子：
2.2
通讯作者：
Sasano, T
中科院分区：
文献类型：
--
作者：
Iikubo, M;Ikeda, H;Sasano, T
为了帮助我们研究肢端肥大症或肢端肥大症的下颌骨扩大的时间过程，以确定这种疾病的咬合治疗的最合适的时期，我们的目的是建立一种大鼠肢端肥大症（肢端肥大症）模型。在这项研究中，突出的下颌骨增大诱导连续皮下输注人重组胰岛素样生长因子-I（IGF-I）（640 μ g/天）在10周龄的雄性大鼠4周（n = 6）;对照假手术组注射生理盐水单独（n = 6）。在四周给药期间，IGF-I组中可清楚地检测到循环人IGF-I，而内源性大鼠IGF-I水平降低。总IGF-I（人+大鼠）在给药期间显著增加，之后恢复至对照水平。与对照组大鼠相比，检查的每根骨（下颌骨、上颌骨和股骨）的长度均显著增加，尤其是下颌骨。虽然在IGF-I给药停止后下颌骨没有继续生长，但与上颌骨和股骨不同，它没有恢复到对照大小，即使在循环IGF-I水平正常化后，不协调的颌骨大小（上颌骨和下颌骨之间）也持续存在。在我们的大鼠模型中的这些发现表明，下颌咬合治疗应仅考虑肢端肥大症（acrogiantic）患者血清IGF-I水平正常化和骨生长停止后。
To help us investigate the time course of mandibular enlargement in acromegaly or acrogiantism to determine the most suitable period for occlusal treatment in this disease, our aim was to develop a rat model of acromegaly (acrogiantism). In this study, prominent mandibular enlargement was induced by continuous subcutaneous infusion of human recombinant insulin-like growth factor-I (IGF-I) (640 mug/day) in 10-week-old male rats for 4 weeks (n = 6); the control sham-operated group was injected with saline alone (n = 6). Circulating human IGF-I was clearly detectable in the IGF-I group during the four-week administration period, while endogenous rat IGF-I levels decreased. Total IGF-I (human + rat) increased significantly during administration, returning to control levels afterwards. The length of every bone examined (mandible, maxilla, and femur) showed a significant increase compared to control rats, especially the mandible. Although the mandible did not continue to grow after discontinuation of IGF-I administration, it did not return to control size, unlike the maxilla and femur, and disharmonious jaw size (between maxilla and mandible) persisted even after circulating IGF-I levels normalized. These findings in our rat model suggest that mandibular occlusal treatment should only be considered for acromegalic (acrogiantic) patients after serum IGF-I levels have normalized and bone growth has ceased.